The securities include (i) 298,647 shares of common stock, $0.00001 par value per share (the "Common Stock") and (ii) 6,367,685 shares of Common Stock issuable upon conversion of 6,367,685 shares of Non-Voting Common Stock, par value $0.00001 per share (the "Non-Voting Common Stock"), the conversion of which is subject to a beneficial ownership limitation of 9.99% of the outstanding Common Stock, both directly held by Fairmount Healthcare Fund II L.P., a Delaware limited partnership ("Fund II"). The securities exclude shares of Common Stock issuable upon conversion of shares of Non-Voting Common Stock held by Fund II in excess of the beneficial ownership limitation. Row 13 is based on 67,754,402 shares of Common Stock outstanding as of March 26, 2026, consisting of (i) 61,302,301 shares of Common Stock outstanding as of March 26, 2026, as reported in the Company's final prospectus supplement filed pursuant to Rule 424(b)(5) dated March 24, 2026, (ii) 84,416 shares underlying vested stock options owned by the Reporting Persons and (iii) 6,367,685 shares of Common Stock underlying the 6,367,685 shares of Non-Voting Common Stock owned by Fund II, applying the beneficial ownership limitation.

The securities include (i) 298,647 shares of Common Stock and (ii) 6,367,685 shares of Common Stock issuable upon conversion of 6,367,685 shares of Non-Voting Common Stock, the conversion of which is subject to a beneficial ownership limitation of 9.99% of the outstanding Common Stock, both directly held by Fund II. The securities exclude shares of Common Stock issuable upon conversion of shares of Non-Voting Common Stock held by Fund II in excess of the beneficial ownership limitation. Row 13 is based on 67,754,402 shares of Common Stock outstanding as of March 26, 2026, consisting of (i) 61,302,301 shares of Common Stock outstanding as of March 26, 2026, as reported in the Company's final prospectus supplement filed pursuant to Rule 424(b)(5) dated March 24, 2026, (ii) 84,416 shares underlying vested stock options owned by the Reporting Persons and (iii) 6,367,685 shares of Common Stock underlying the 6,367,685 shares of Non-Voting Common Stock owned by Fund II, applying the beneficial ownership limitation.

The securities include (a) 51,166 shares of Common Stock held directly by Mr. Harwin, (b) 42,208 shares of Common Stock underlying vested options held by Mr. Harwin* and (c) Fund II's direct holdings of (i) 298,647 shares of Common Stock and (ii) 6,372,953 shares of Common Stock issuable upon conversion of 6,372,953 shares of Non-Voting Common Stock, the conversion of which is subject to a beneficial ownership limitation of 9.99% of the outstanding Common Stock. The securities exclude shares of Common Stock issuable upon conversion of shares of Non-Voting Common Stock in excess of the beneficial ownership limitation. Row 13 is based on 67,717,462 shares of Common Stock outstanding as of March 26, 2026, consisting of (i) 61,302,301 shares of Common Stock outstanding as of March 26, 2026, as reported in the Company's final prospectus supplement filed pursuant to Rule 424(b)(5) dated March 24, 2026, (ii) 42,208 shares of Common Stock underlying vested options held by Mr. Harwin and (iii) 6,372,953 shares of Common Stock underlying the 6,372,953 shares of Non-Voting Common Stock owned by Fund II, subject to the beneficial ownership limitation. * Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the options for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock.

The securities include (a) 51,166 shares of Common Stock held directly by Mr. Kiselak, (b) 42,208 shares of Common Stock underlying vested options held by Mr. Kiselak* and (c) Fund II's direct holdings of (i) 298,647 shares of Common Stock and (ii) 6,372,953 shares of Common Stock issuable upon conversion of 6,372,953 shares of Non-Voting Common Stock, the conversion of which is subject to a beneficial ownership limitation of 9.99% of the outstanding Common Stock. The securities exclude shares of Common Stock issuable upon conversion of shares of Non-Voting Common Stock in excess of the beneficial ownership limitation. Row 13 is based on 67,717,462 shares of Common Stock outstanding as of March 26, 2026, consisting of (i) 61,302,301 shares of Common Stock outstanding as of March 26, 2026, as reported in the Company's final prospectus supplement filed pursuant to Rule 424(b)(5) dated March 24, 2026, (ii) 42,208 shares of Common Stock underlying vested options held by Mr. Kiselak and (iii) 6,372,953 shares of Common Stock underlying the 6,372,953 shares of Non-Voting Common Stock owned by Fund II, subject to the beneficial ownership limitation. * Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the options for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock.